US 12,083,176 B2
Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
Corinne Hanotin, Paris (FR); Laurence Bessac, Paris (FR); and Umesh Chaudhari, Bridgewater, NJ (US)
Assigned to SANOFI BIOTECHNOLOGY, Gentilly (FR)
Filed by Sanofi Biotechnology, Paris (FR)
Filed on Dec. 23, 2021, as Appl. No. 17/560,402.
Application 15/389,130 is a division of application No. 13/982,373, granted, now 9,561,155, issued on Feb. 7, 2017, previously published as PCT/EP2012/051320, filed on Jan. 27, 2012.
Application 17/560,402 is a continuation of application No. 16/365,317, filed on Mar. 26, 2019, granted, now 11,246,925.
Application 16/365,317 is a continuation of application No. 15/389,130, filed on Dec. 22, 2016, abandoned.
Claims priority of application No. 11305088 (EP), filed on Jan. 28, 2011; application No. 11305089 (EP), filed on Jan. 28, 2011; application No. 11305513 (EP), filed on Apr. 29, 2011; application No. 11305514 (EP), filed on Apr. 29, 2011; application No. 11306039 (EP), filed on Aug. 12, 2011; application No. 11306040 (EP), filed on Aug. 12, 2011; application No. 11306201 (EP), filed on Sep. 22, 2011; application No. 11306202 (EP), filed on Sep. 22, 2011; application No. 11306449 (EP), filed on Nov. 8, 2011; and application No. 11306450 (EP), filed on Nov. 8, 2011.
Prior Publication US 2022/0218823 A1, Jul. 14, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/40 (2006.01); A61K 39/395 (2006.01); A61P 3/06 (2006.01); A61J 1/05 (2006.01); A61K 31/215 (2006.01); A61K 31/366 (2006.01); A61K 31/404 (2006.01); A61K 31/435 (2006.01); A61K 31/47 (2006.01); A61K 31/505 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); C07K 14/47 (2006.01)
CPC A61K 39/3955 (2013.01) [A61P 3/06 (2018.01); C07K 16/40 (2013.01); A61J 1/05 (2013.01); A61K 31/215 (2013.01); A61K 31/366 (2013.01); A61K 31/404 (2013.01); A61K 31/435 (2013.01); A61K 31/47 (2013.01); A61K 31/505 (2013.01); A61K 39/395 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); A61K 45/06 (2013.01); C07K 14/4703 (2013.01); C07K 2317/21 (2013.01); C07K 2317/76 (2013.01)] 10 Claims
 
1. A pharmaceutical composition comprising:
75 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (hPCSK9) at a concentration of 75 mg/ml, or
150 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (hPCSK9) at a concentration of 150 mg/ml, or
300 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (hPCSK9) at a concentration of 300 mg/ml;
together with a pharmaceutically acceptable excipient or carrier,
wherein the antibody or antigen-binding fragment thereof comprises the three heavy chain CDRs set forth in SEQ ID NOs: 76, 78, and 80 and the three light chain CDRs set forth in SEQ ID NOs: 84, 86, and 88.